A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
New England Journal of Medicine2005Vol. 352(17), pp. 1779–1790
Citations Over TimeTop 1% of 2005 papers
Róbert Královics, Francesco Passamonti, Andreas Buser, Soon-Siong Teo, Ralph Tiedt, Jakob Passweg, André Tichelli, Mario Cazzola, Radek C. Skoda
Abstract
A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
Related Papers
- → The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis(2014)55 cited
- → Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without JAK2 V617F(2014)21 cited
- → Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis(2022)17 cited
- → Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis(2017)1 cited
- → Myeloproliferative Neoplasms: Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis(2009)1 cited